Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Significant Decrease in Short Interest

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the recipient of a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 350,900 shares, a decline of 37.9% from the October 15th total of 565,500 shares. Based on an average daily volume of 281,500 shares, the days-to-cover ratio is presently 1.2 days. Currently, 7.6% of the company’s shares are sold short.

Virpax Pharmaceuticals Trading Down 3.8 %

VRPX traded down $0.02 during trading on Friday, hitting $0.62. The company had a trading volume of 73,321 shares, compared to its average volume of 1,798,571. Virpax Pharmaceuticals has a 1-year low of $0.36 and a 1-year high of $8.00. The business has a 50-day moving average of $0.67 and a 200-day moving average of $0.96.

Virpax Pharmaceuticals (NASDAQ:VRPX) last issued its quarterly earnings results on Monday, August 12th. The company reported ($1.75) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Separately, Maxim Group restated a “hold” rating on shares of Virpax Pharmaceuticals in a research note on Wednesday, October 9th.

Hedge Funds Weigh In On Virpax Pharmaceuticals

A hedge fund recently bought a new stake in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC purchased a new stake in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned 1.17% of Virpax Pharmaceuticals as of its most recent filing with the SEC. 32.23% of the stock is owned by institutional investors and hedge funds.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.